Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401805 | 0.91 | CTRB1 (0.60) | CTRB1ELANEKCNQ4KCNQ5CTSS | |
| SCHEMBL6398072 | 0.90 | CTRB1 (0.51) | CTRB1ELANEKCNQ4KCNQ5HDAC6 | |
| SCHEMBL6401804 | 0.83 | ELANE (0.54) | CTRB1ELANEP2RX7P2RX3LCK | |
| SCHEMBL6402812 | 0.82 | ELANE (0.56) | CTRB1ELANEKCNQ4KCNQ5CTSS | |
| SCHEMBL6401408 | 0.82 | CTRB1 (0.54) | CTRB1ELANEP2RX7 | |
| SCHEMBL6400204 | 0.80 | ELANE (0.65) | CTRB1ELANEP2RX7LCKMAPT | |
| SCHEMBL6866267 | 0.78 | ELANE (0.80) | CTRB1ELANELCK | |
| SCHEMBL6500227 | 0.78 | CTRB1 (0.59) | CTRB1ELANEHDAC6P2RX7LCK | |
| SCHEMBL6637522 | 0.77 | CTRB1 (0.47) | CTRB1ELANECYP17A1 | |
| SCHEMBL6637260 | 0.77 | CTRB1 (0.46) | CTRB1ELANECYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | claimed |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6806269-B1 | EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE | G. D. SEARLE & COP | 2004-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | CTRB1 3288/4885ELANE 1052/4885KCNQ4 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.